The Deal Register
Database › Equity financing › Optimi Health Announces Pricing of Oversubscribed US$15 Million…

Equity financing

Optimi Health Announces Pricing of Oversubscribed US$15 Million Public Offering and Nasdaq Uplisting

Lane
Equity financing
Announced
20 May 2026
Province
British Columbia
Industry
Healthcare & life sciences
Status
Announced
What the filing says
Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage pharmaceutical company focused on manufacturing and distributing finished psychedelic drug products, today announced the pricing of its underwritten public offering (the " Offering") in connection with the uplisting of its common shares to the Nasdaq Capital Market.
Terms stated
price per security
Source

The terms are in the subscriber edition

This transaction carries 1 stated term, with its value, unit and basis and the consideration.

Subscribe

Compiled from public filings, court documents, exchange bulletins and issuer releases. Figures are as disclosed and are not independently verified.

Not financial, investment, legal or tax advice, and not an offer to buy or sell any security. Verify everything before you transact.

The Deal Register · Archive · Subscribe